Skip to main content
. 2021 Dec 14;13(3):322–337. doi: 10.1111/1759-7714.14244

TABLE 2.

Patient characteristics of the included studies

Study name Total N PD‐L1 level (experiment/control) Age (median) (experiment/Control) Male (n,%) (experiment/control)
≥50% 1%–50% ≤1%
Checkmate 026 541 88/126 208/210 0 63.0/65.0 184(67.9)/148(54.8)
Keynote 189 616 132/70 128/58 127/63 65.0/63.5 254(62.0)/109(52.9)
Keynote 407 559 73/73 103/104 95/99 65.5/65.0 220(79.1)/235(83.6)
Checkmate 227 1739 205/214/192 (Nivo+Ipi/Nivo/Chemo) 191/182/205 (Nivo+Ipi/Nivo/Chemo) 187/177/186 (Nivo+Ipi/Nivo+Chemo/Chemo)

64.0/64.0/64.0 (Nivo+Ipili/Nivo/Chemo)

63.0/64.0/64.0 (Nivo+Ipi/Nivo+Chemo/Chemo)

255 (64.4)/272 (68.7)/260 (65.5) (Nivo+Ipili/Nivo/Chemo)

138(73.8)/130(73.4)/125(67.2) (Nivo+Ipili/Nivo+Chemo/Chemo)

IMpower 130 679 88/42 128/65 235/121 64.0/65.0 266(59.0)/134(58.8)
IMpower 131 683 47/44 136/125 160/171 65.5/65.0 279(81.0)/278(82.0)
IMpower 132 578 25/20 63/73 88/75 64.0/63.0 192(65.8)/192(67.1)
Keynote 021G 123 20/17 19/23 21/23 62.5/63.2 22(37.0)/26(41.0)
Keynote 024 305 125/124 0 0 64.5/66.0 92(59.7)/95(62.9)
Keynote 042 1273 299/300 338/337 0 63.0/63.0 450(70.6)/452(71.0)
MYSTIC 1092 118/108/107 (Durva/Durva+Treme/Chemo) NA 95/76/83 (Durva/Durva+Treme/Chemo) 64.0/65.0/64.5 113 (69.3) /118 (72.4) /106 (65.4)
IMpower 110 554 107/98 170/179 0 64.0/65.0 196(70.8)/196(69.7)
Camel 412 49/69 108/97 30/20 59.0/61.0 146(71.2)/149(72)
Study name Nonsquamous (n,%)(Experiment/Control) Never Smoked (n,%)(Experiment/Control) ECOG 0(n,%) CNS metastasis (n,%) Asia
Checkmate 026 205 (76)/206(76) 30 (11)/29 (11) 85 (31)/93 (34) 33 (12)/36 (13) 30(11)/17 (6.3)
Keynote 189 410 (100)/206(100) 48 (11.7)/25 (12.1) 186 (45.4)/80 (38.8) 73 (17.8)/35 (17) 4 (1)/6 (2.9)
Keynote 407 0/0 22 (7.9)/19 (6.8) 73 (26.3)/90 (32.0) 20 (7.2)/24 (8.5) 54 (19.4)/52 (18.5)
Checkmate 227

279 (70.5)/279 (70.5)/281 (70.8)

(Nivo+Ipi/Nivo/Chemo)

140 (74.9)/134 (75.7)/140 (75.3)

(Nivo+Ipi/Nivo+Chemo/Chemo)

56 (14.1)/50 (12.6)/51 (12.8)

(Nivo+Ipi/Nivo/Chemo)

23 (12.3)/27 (15.3)/27 (14.5)

(Nivo+Ipi/Nivo+Chemo/Chemo)

135 (34.1)/142 (35.9)/134 (33.8)

(Nivo+Ipi/Nivo/Chemo)

69 (36.9)/59 (33.3)/57 (30.6)

(Nivo+Ipi/Nivo+Chemo/Chemo)

41 (10.4)/42 (10.6)/40 (10.1)

(Nivo+Ipi/Nivo/Chemo)

23 (12.3)/16 (9.0)/11 (5.9)

(Nivo+Ipi/Nivo+Chemo/

Chemo)

81 (20.5)/66 (16.7)/81 (20.4)

(Nivo+Ipi/Nivo/Chemo)

40 (21.4)/36 (20.3)/43 (23.1)

(Nivo+Ipi/Nivo+Chemo/Chemo)

IMpower 130 451 (100)/228 (100) 48 (11)/17(7) 189 (42%)/91 (40%) NG 12 (3)/3(1)
IMpower 131 0/0 32 (9.3)/23(6.8) 115 (33.5)/110 (32.4) NG 41 (12.0)/37 (10.9)
IMpower 132 292 (100)/286 (100) 37 (12.7)/30(10.5) 126 (43)/114 (40) NG 71 (24.3)/65 (22.7)
Keynote 021G 60 (100)/63 (100) 15 (25)/9(14) 24 (40) /29 (46) 9 (15)/6 (10) 5 (8)/5 (8)
Keynote 024 125 (81.2)/124 (82.1) 5 (3.2) /19(12.6) 54 (35.1)/53 (35.1) 18 (11.7)/10 (6.6) 21(13.6) 19 (12.6)
Keynote 042 394 (62)/388(61) 142 (22)/140 (22) 198 (31)/192 (30) 35 (5)/35 (5) 85 (29)/185 (29)
MYSTIC

111 (68.1)/ 110 (67.5)/110 (67.9)

(Durva/Durva+Treme/Chemo)

24 (14.7)/ 25 (15.3)/21 (13.0)

(Durva/Durva+Treme/Chemo)

57 (35.0)/65 (39.9)/70 (43.2)

(Durva/Durva+Treme/Chemo)

NG

59 (36.2)/50 (30.7) /47 (29.0)

(Durva/Durva+Treme/Chemo)

IMpower 110 277 (100)/277 (100) 37 (13.4)/35 (12.6) 97 (35.0)/102 (36.8) NG 45 (16.2)/30 (10.8)
Camel 205 (100)/207 (100) NA/NA 48 (23.4)/36 (17.5) 10 (5)/5 (2) NG

Abbreviations: Camre, camrelizumab; Chemo, chemotherapy; Durva, durvalumab; Ipi, ipilimumab; Nivo, nivolumab; Treme, tremelimumab.